Formulation and Evaluation of Therapeutic Potential of Nanoemulsion of a Blend of Antimicrobial Oils

Uduma E. Osonwa1*, Simeon A. Okechukwu1, Chibueze P. Ikekeremem2, Kingsley I. Chukwu3, Stanley C. Eluu4, Ricardo B. Azevedo5

1Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka 420281, Nigeria.
2Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka 420281, Nigeria.
3Department of Pharmaceutics, College of Pharmacy and Nutrition, University of Saskatchewan, Canada.
4Department of Biotechnology, Ebonyi State University, Abakaliki, Ebonyi State, Nigeria.
5Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasilia, Brazil.

ABSTRACT

This work is aimed at producing an effective self-emulsifying nanoformulation of a combination of 9 antimicrobial edible plant oils against bacterial and fungal infections. The oils are olive, eucalyptus, dill, castor, peppermint, garlic, ginger, sunflower and lemongrass oils. Oil Formulation (OF) was produced by mixing a simple Oil Blend (OB) of the oils with polysorbate 80 at the ratio of 1:4. Particle size distribution, polydispersity index and zeta potential of OF and Nanoemulsion (NE) were determined. The antimicrobial properties of OB and OF were determined using selected bacteria and fungi. The most sensitive bacteria and fungi were then selected for in vivo assay of OB and OF using albino Wistar rats (n=5). Oral treatment began 4 days post-infection and lasted 5 days. Ciprofloxacin and Ketoconazole were used as positive controls. Safety screenings (hematological, liver function tests (LFT’s) and histological) were then conducted. The results showed that the optimal Oil/Polyisorbate 80 ratio was 1:4. NE had mean particle size (151.12 ± 6.21) nm, polydispersity index (0.12) and zeta potential (-13.70 ± 4.40) mV, which after 90 days became (202.50 ± 4.11) nm, 0.09, and (35.00 ± 6.15) mV respectively. OF had mean particle size (158.00 ± 3.08) nm, polydispersity index (0.07) and zeta potential (35.00 ± 6.15) mV respectively. particle size (151.12 ± 6.21) nm, polydispersity index (0.12) and zeta potential (-13.70 ± 4.40) mV, which after 90 days became (202.50 ± 4.11) nm, 0.09, and (35.00 ± 6.15) mV respectively. OF and NE were selected for in vivo assay of OB and OF using albino Wistar rats (n=5). Oral treatment began 4 days post-infection and lasted 5 days. Ciprofloxacin and Ketoconazole were used as positive controls. Safety screenings (hematological, liver function tests (LFT’s) and histological) were then conducted. The results showed that the optimal Oil/Polyisorbate 80 ratio was 1:4. NE had mean particle size (151.12 ± 6.21) nm, polydispersity index (0.12) and zeta potential (-13.70 ± 4.40) mV, which after 90 days became (202.50 ± 4.11) nm, 0.09, and (35.00 ± 6.15) mV respectively. OF had mean particle size (158.00 ± 3.08) nm, polydispersity index (0.07) and zeta potential (-15.50 ± 3.01) mV, which after 90 days became (162.90 ± 6.01) nm, 0.08, and (-19.00 ± 0.00) mV respectively. Nanoemulsion formulation of the oil blend significantly (p<0.05) improved antimicrobial activity in infections of Staphylococcus aureus and Aspergillus niger and it was not toxic to the rats.

Keywords: Nanoemulsion, Formulation, Antimicrobial oils, Therapeutic potential, Safety.

Introduction

There is a growing need to combat antibiotic resistance, or at least enhance antimicrobial activity against resistant organisms through formulation.1 Possible solutions may lie in the use of herbs or their products.2 There have been reports of synergism among herbal products3 and some natural oils derived from plants possess antimicrobial properties.4 The oils of Mentha piperita (peppermint),5 Cymbopogon citratus (lemon grass)6,7 and Eucalyptus8,9 have been reported to possess antibacterial, antiviral and antifungal properties. Even though the chemical composition of the essential oil of Cymbopogon citratus (lemon grass) varies according to the geographical origin,10 some species have demonstrated activity against these organisms. Eucalyptus oil has been reported to show activity against Herpes simplex viruses,11 some strains of Escherichia coli,12 Pseudomonas aeruginosa, Streptococcus faecalis, Candida albicans, and Aspergillus flavus.13,14 Similarly, castor oil is a known source of ricinoleic acid, possess antibacterial and antifungal activity.12

The oil of Anethum graveolens (dill oil) is also reported to possess antibacterial and antifungal activity.15,16 Allium sativum (garlic) possesses antifungal and antibacterial properties and is associated with allicin, ajoene, thiosulfimates and a wide range of other organophosphate compounds.16 Its antibacterial spectrum covers Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus epidermidis and Klebsella pneumonia.17,18 Zingiber officinale (ginger) has activity against some Gram-positive and Gram-negative bacteria including Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae and Haemophilus influenza.19,20 Gingerols and gingerdil from ginger are identified as being active against 13 human pathogens.21 Helianthus annuus (Sunflower) seed oil has antifungal and antibacterial properties.22 Oleic acid, phenolic constituents, and squalene are the major active components of the fruit of Olea europaea (olive oil).24 Olive oil has demonstrated activity against a variety of organisms including intestinal and respiratory pathogens.24 A combination of these oils will potentially have a broad spectrum of activity, and may also be an important agent against resistant organism due to their multicomponent nature. These oils are miscible and multicomponent in nature and they may have the capacity to withstand microbial resistance by acting synergistically against organisms that are normally resistant to single molecules. More so, these oils are edible and generally regarded as safe. The present work is therefore aimed at formulating the selected oils into a nanoemulsion system for treatment in cases of bacterial and fungal infections possibly occurring together.

*Corresponding author. E-mail: udumaoxonwa@yahoo.com Tel: +2348038733305

Citation: Osonwa UE, Okechukwu SA, Ikekeremem CP, Chukwu KI, Eluu SC, Azevedo RB. Formulation and Evaluation of Therapeutic Potential of Nanoemulsion of a Blend of Antimicrobial Oils. Trop J Nat Prod Res. 2018; 2(2):67-73. doi:10.26538/tjnpr/v2i2.3

© 2018 Natural Product Research Group, Faculty of Pharmacy, University of Benin. All rights reserved.
Materials and Methods

Reagents:
The following reagents were purchased from a local supplier: ketoconazole 200 mg tablets (Hovid Bhd, Malaysia), ciprofloxacin 500 mg tablets (Fidson Healthcare, Limited, Nigeria). They were standardized in terms of drug content and release. Olive, eucalyptus, dill, castor and peppermint oils were purchased from a local supplier (Anselem Chemicals, Nigeria). Garlic, ginger, sunflower and lemongrass oils were donated by the Nanobiotechnology Laboratory, Department of Genetics and Morphology, University of Brasilia, Brazil.

Other reagents were immersion oil (Panzonar Laboratory Supplies, Canada), alanine aminotransferase and aspartate aminotransferase (Randox Laboratory, UK), chloroform (Sigma-Aldrich, USA), Drabkin’s solution (Organico Biotech. Laboratories, India), EDTA (Fushun Shunnun Chemical, China), paraffin wax (Green Mountain, China), xylene (Shivan Industries, India), haematoxylin (Abbey Colour, Philadelphia), eosine (Abbey Colour, Philadelphia), RBC diluting fluid (Organico Biotech. Laboratories, India), WBC diluting fluid (Alpha Chemicals, India), formal saline (Vet Way Industries, UK), phosphate buffer (Vet Way Industries, UK) and Polysorbate 80 (Sigma-Aldrich, Brazil).

Experimental Animals:
Forty-five (45) Wistar rats of both sexes weighing 108-188 g and twelve albino, five (5) each of both sexes weighing 18-22 g were acquired from the Animal House of the Department of Veterinary Medicine, University of Nigeria, Nsukka. They were housed in groups of three in an environment with controlled conditions of humidity and 12 h light and darkness cycles. They were given rodent feed ad libitum and had unrestricted access to water during the adaptation period of 7 days.

Microbial culture:
Clinical isolates of Gram-positive (Staphylococcus aureus, Enterococcus faecalis, Bacillus subtilis) and Gram-negative (Pseudomonas aeruginosa, Klebsiella pneumonia, Escherichia coli, Salmonella typhi) bacteria and fungi (Candida albicans and Aspergillus niger) were previously isolated from clinical samples and maintained in the Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka. These microorganisms were used in this study.

Formulation and Characterization of the Nanoemulsion System:
A blend of the 9 oils with antimicrobial properties (olive oil, eucalyptus oil, dill oil, castor oil, peppermint oil, garlic oil, ginger oil, sunflower oil and lemongrass oil) was produced by introducing eight milliliters (8 mL) of each in a 200-mL beaker and gently blending for 10 min, using a magnetic stirrer (model RH IKA Labortechnik, Germany). This was designated as Oil Blend (OB). Using a predetermined ratio, calculated quantities of polysorbate 80 and water were introduced and blended together for another 10 min. A total of twelve (12) different formulations were made. The products were stored and observed for one week. The ratio of oil to polysorbate 80 that forms stable, freely miscible oil-in-water nanoemulsion was selected as desired one, and designated NE, while the corresponding oil-surfactant blend was selected as the desired Oil Formulation (OF). One preparation each of the OB, OF and NE was made. The products were stored and observed for one week. The particle size, polydispersity index (pdi) and zeta potential of NE and OF were measured using Zetasizer (Malvern, USA) after five serial dilutions with distilled water. The colonies of bacteria and spores of fungi were counted using a counting chamber. The oral median lethal dose (LD50) of OB was determined by the method of Lorke26 with the white albino mice and observed.

In vivo Antimicrobial Assay:
In this experiment, only 24 h-cultures of Staphylococcus aureus and Aspergillus niger were used because of their highest sensitivity to OB and OF in the in vitro antimicrobial assay. Nine (9) groups of five animals (n = 5) each were randomized into three categories of four groups for antibacterial studies, another four groups for antifungal studies. One group served as a reference for both studies. Except for the reference group, the animals were infected with the pathogenic microorganisms (0.1 mL of 10^5 CFU), according to McFarland’s dilution standards, using sterile hypodermic 1 mL syringe. The reference category was neither infected nor treated. Out of the four groups used for the antifungal studies category, one group was infected but not treated, serving as the negative control. Another group that was infected but treated for 5 days with ketoconazole (2.86 mg/kg/day) served as a positive control. The remaining two groups in this category were infected and treated with either OB or OF. In antibacterial study category, the negative control group was infected with S. aureus but not treated while a positive control group was infected with S. aureus and treated with a daily ciprofloxacin dose (7.14 mg/kg) for 5 days. The remaining two groups also received either OB or OF as treatment post infection. The doses of the OB and OF administered were 0.37 mL/kg/day OB (1/50th of the LD50) and 1.85 mL/kg OF (equivalent doses based on density calculations). Treatments were started 4 days post-infection. Samples of whole blood (0.5 mL) were taken from the animals on days 1, 3 and 5 post-treatment from the lateral canthus of the eyes. The microbial load of the organisms (S. aureus, A. niger) in blood were assessed by culturing a 10-fold dilution of the blood samples. The colonies of bacteria and spores of fungi were physically counted using tally counter after 24 h (S. aureus and 48 h (A. niger).

Hematological Parameters Assessment:
Three days post-treatment; blood samples were collected from the medial canthus of each rat using a capillary tube. The blood samples were used to determine the PCV, hemoglobin, total red blood cell (RBC), and total white blood cell (WBC) of the rats using standard method.27

Assessment of Biochemical Parameters:
At the end of the test period, the rats were sacrificed. Blood samples were collected from each experimental rat by cardiac puncture. The blood samples were centrifuged to obtain sera which were stored at 4°C until further assay. The stored sera were used for assessment of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) after first warming to room temperature. AST and ALT activities were determined by the methods of Reitman and Frankel28 as outlined in Randox kit (Randox Laboratories, UK). Activities were expressed as IU/L.

Histopathological assessment:
Histopathological changes of the liver and kidney of each rat in the respective categories and groups were assessed after treatment. Tissue sections of the liver and kidney were fixed in 10% formal saline and dehydrated in 80% ethanol overnight and then in 100% ethanol for one hour. Thereafter, the tissues were cleared in chloroform overnight, infiltrated and embedded in molten paraffin wax. The paraffin blocks were later mounted and sectioned with a rotary microtome (HM-325) at a 5-6 microns thickness. Sections were deparaffinized in xylene and subsequently stained with Haematoxylin and Eosin (H and E) for light microscopy.30

Statistical Analysis:
Means and standard deviations of all readings obtained during the characterization of OF and OB, were calculated using Microsoft (MS) Excel. ANOVA was done using SPSS version 16.0 at 5% level of significance.
Results and Discussion

**Formulation Characteristics**

The mean particle size, polydispersity index (pdi) and zeta potential of the freshly formulated NE were 151.12 ± 6.21 nm, 0.12 and -13.70 ± 4.40 mV, respectively and after 90 days became 202.50 ± 4.11 nm, 0.09, and -35.00 ± 6.15 mV, respectively. The readings for the fresh OB were 158.00 ± 3.08 nm, 0.07, and -15.50 ± 3.01 mV, respectively and after 90 days became 162.90 ± 6.01 nm, 0.08, and 19.00 ± 0.00 mV, respectively. Hence, NE was not used for further assays since it is not stable on prolonged storage. These results are shown in Figures 1-3. Gentle agitation of OF with water forms a stable uniform phase.

The size range achieved has been reported to enhance the activity of antimicrobial agents.31,32 Nanostructures are achieved when they are less than 500 nm. The more the number of structures with larger sizes, the more unstable the formulation becomes. The result of the size analysis shows it conforms to the size range of nanoemulsions. The pdi is an indication of the width of the particle size distribution. The pdi value that reflects the quality of the dispersion usually ranges from 0 to 0.5. Pdi values ≤ 0.1 indicate the highest quality of dispersion. Although, most researchers rate pdi values ≤ 0.3 as optimal, values ≤ 0.5 may be acceptable.33 The pdi values of the nanoemulsion were within the acceptable range.

Aggregation of suspended particles results in formation of larger particles which quickly results in unstable formulation. As a result, the degree of repulsion between similarly charged particles in a formulation during storage shows how stable a suspension is. This repulsive force, measured through the zeta potential is indicative of physical stability of a formulation.34 A minimum zeta potential of about –60 mV yields a formulation with excellent physical stability, while a zeta potential of approximately ~30 mV yields a formulation with fairly good physical stability.35 The range of values of our formulation suggests a product with good physical stability.

**In vitro Antimicrobial Assay**

The values of MIC of OB against S. aureus, S. typhi, C. albicans and A. niger were ≤ 1.25 µL/mL. E. coli, E. fecalis and B. subtilis, had values between 2.5 µL/mL - 10 µL/mL (Table 3). P. aeruginosa and K. pneumonia had values ≥ 20.0 µL/mL. The most sensitive organisms (C. albicans, A. niger) recorded 0.63 µL/mL while P. aeruginosa was resistant at the highest concentration used. For the OF, S. aureus (3.125 µL/mL) and K. pneumonia was the most sensitive. Some of the organisms (S. typhi, E. fecalis, C. albicans, A. niger) recorded an MIC between 12.5 µL/mL - 25 µL/mL while E. coli, B. subtilis and K. pneumonia had a value range 50 – 100 µL/mL. Though B. subtilis (3.12 µg/mL) was the most sensitive to the positive antibacterial control (ciprofloxacin), all the sample bacteria recorded sensitivity within the range of 3.12 µg/mL and 25 µg/mL. P. aeruginosa (25 µg/mL) and S. typhi (25 µg/mL) were the least sensitive. Intermediate values were obtained at 6.25 µg/mL (S. aureus, E. fecalis) and 12.5 µg/mL (E. coli, K. pneumonia). In comparison, OB had lower MIC values than their corresponding values for OF (Table 1). The lowest MIC recorded for OB and OF were 0.625 µL/mL (A. niger and C. albicans) and 3.125 µL/mL (S. aureus), respectively. All the organisms except P. aeruginosa were sensitive at the maximum concentration used. When OB and OF are compared based on equivalent oil content, OB recorded a lower MIC than OF for all the organisms except for K. pneumonia (Figure 1). Ciprofloxacin had its lowest MIC (3.125 µg/mL) on Bacillus subtilis while OB and OF recorded MICs of 5 µL/mL and 20 µL/mL, respectively on the same organism. With the fungus, Candida albicans, ketoconazole recorded the lowest MIC (0.25 µg/mL), while OB and OF recorded MICs of 0.625 µL/mL and 5 µL/mL, respectively. Results of the in vitro MIC assay show that OB has a lower MIC for most of the organisms than OF. The higher MIC value of OF was probably due to the poor dispersion of OF in the incubation medium. Poor dispersion possibly resulted from the absence of water, which could have been an agent for nanoemulsification. Another source of poor dispersion could be the excipients in OF. Presence of formulation excipients may affect the dispersion profile of an active drug principle in a medium. However, the results may not be representative of what happens inside the body.

**In Vivo Studies**

**Efficacy Studies**

The antifungal count showed that the results for the positive control (ketoconazole treated group), OB and OF were similar and there was no significant difference (p > 0.05) between the ketoconazole group and OF. After 5 days, the fungal load was reduced to 55%, 71% and 60% with ketoconazole, OB and OF, respectively (Figure 4). Overall, results of the in vivo experiments for both bacteria and fungi show that OB performed better than OF in microbial elimination. Consequently, the studies imply that nanoemulsification improved microbial clearance since the equivalent dose of oil was used both in OB and OF. The improved performance in in vivo studies may be due to in situ nanoemulsification, which is facilitated by agitation that accompanies both swallowing, and peristaltic movement of the gastrointestinal tract, thus enhancing absorption.

**Safety Studies**

LD50

The LD50 of the formulation was calculated to be 18.5 mL/kg equivalent to 15,910 mg/kg based on a calculated relative density of 0.86 mg/mL. The result of the acute toxicity test shows that the formula is safe.

---

**Figure 1:** Stability results of the preparations showing changes in particle size

**Figure 2:** Stability results of the preparations showing changes in Zeta potential
**Effect of treatment on hematopoietic parameters**

The order of improvement in PCV (Figure 6) was ciprofloxacin = OF > OB for the bacteria-infected group. There were no significant differences in PCV for the fungus-infected animals (Figure 7). The test samples showed an improvement in RBC count in both infections (bacterial and fungal).

All other treated animals performed better than the ketoconazole-treated group. All the groups infected but treated showed improvement in hemoglobin content in both infections (bacteria and fungi) (Figure 8). The effect on hemoglobin content for all the animals treated with the test sample was comparable to that of the uninfected animals. The results suggest that OF and OB do not cause erythrocytopenia, unlike ketoconazole treatment, which showed some adverse effects.

WBC results (Figure 9) show that infection increases WBC count (p < 0.05). All the interventions ameliorated the effect of infection on WBC count (Figure 9). Values for OB and ciprofloxacin were similar in bacteria-infected groups. Ketoconazole-treated group had less WBC count increase than OB, OF, or ciprofloxacin-treated groups.

Hematological indices are reliable parameter for assessment of health status of animals. The severity of hematopoietic changes depends on the species, physiological state of the host, and acuteness or chronicity of the infection. Since there is no significant difference (p < 0.05) in RBC or PCV of pre-infected animals, it is taken that all the groups were of similar health status before treatment. The post-treatment values of PCV and RBC count indicates the level of correlation with microbial clearance. More adverse effects were observed with the bacteria-infected groups, than with the fungus A. niger. Immune-mediated hemolysis in infection may result from the production of hemolytic antibodies. Hemolysis may also be initiated by chemicals or metabolites that result in erythrocyte membrane damage. The damaged RBCs are subsequently recognized by splenic macrophages and destroyed.

Increase in WBC count usually arises as an immune defense mechanism against invading microorganisms or foreign particles. The reduction in WBC count for the treated groups is associated with microbial reduction arising from treatment. With OB and OF, like ketoconazole and ciprofloxacin WBC proliferation was reduced.

**Effect of Treatment on Liver**

The liver function tests AST, ALP, and ALT give a good indication of the condition of the liver. Increase in plasma level of the hepatic enzyme may be due to injury or altered liver cell integrity caused by infection. The amount of these enzymes in the blood is used as a measure of the extent of damage sustained. The interventions mitigated the increases in ALP in both infections (bacterial and fungal) (Figure 10). The effect of treatment on ALP for all the animals treated with the test samples showed slight increases (≤ 15%) in values when compared with the uninfected group. All interventions ameliorated the effect of infection on AST (Figure 11) for all the animals. Values for OB, OF, and ketoconazole were similar (p > 0.05) in fungal infection. On the other hand, ciprofloxacin showed less increase with OB and OF.

Figure 12 shows photomicrographs of liver sections of the rats. Varying degrees of portal hepatitis (mainly mononuclear cell infiltration of the portal area-P) are associated with the controls (negative and positive) of both the fungal and bacteria-infected groups. OB showed varying degrees of portal mononuclear cell infiltration of cells both in the bacterial and fungal group. In addition, there was vascular congestion observed with negative control (fungal), ketoconazole and OB. There was no observable histopathological change associated with OF in both the fungal and bacterial groups. The results from the liver studies show that OF is safe on the liver.
Table 1: Results of *In vitro* MIC Screening.

| Conc (µg/mL) → | OB | OF | OB | OB | OF | OB | OB | OB | OF | OB | OF | OF | OF | OF |
|---------------|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| 20            | -  | -  | -  | -  | -  | -  | -  | -  | -  | MIC | -  | +  | MIC | +  |
| 100           | -  | MIC| MIC| +  | +  | +  | +  | +  | +  | +  | +  | +  | +  | +  |
| 50            | +  | +  | +  | +  | +  | +  | +  | +  | +  | +  | +  | +  | +  | +  |
| 25            | -  | +  | -  | +  | MIC| +  | +  | +  | +  | +  | +  | +  | +  | +  |
| 12.5          | -  | -  | -  | -  | -  | MIC| -  | +  | MIC| +  | +  | +  | +  | +  |
| 6.3           | -  | -  | -  | -  | -  | -  | -  | +  | +  | +  | +  | +  | +  | +  |
| 3.1           | -  | -  | -  | -  | -  | -  | -  | -  | +  | +  | +  | +  | +  | +  |
| 1.6           | -  | -  | -  | -  | -  | -  | -  | -  | -  | +  | +  | +  | +  | +  |

- = NO GROWTH; + = GROWTH; MIC = Minimum Inhibitory Concentration.

Figure 6: Effect of treatment on packed cell volume.

* Significant difference at p<0.05 when compared to uninfected group.

Figure 7: Effect of treatment on RBC.

Figure 8: Effect of treatment on hemoglobin (Hb).

* Significant difference at P < 0.05 when compared to uninfected group.

Figure 9: Effect of treatment on White blood cells (WBC).

Figure 10: Effect of treatment on ALT.

Figure 11: Effect of treatment on AST.
In conclusion, this pilot study has demonstrated that the formulation of a blend of antimicrobial oils into nanoemulsion resulted in significant microbial clearance in vivo, which, possibly is due to improved bioavailability. Acute toxicological, hematological and hepatological studies show that the nanoemulsion is safe for consumption. Further studies will be needed to improve and comprehensively characterize the stability of the product over time.

Conflict of interest
The authors declare no conflict of interest.

Authors’ Declaration
The authors hereby declare that the work presented in this article is original and that any liability for claims relating to the content of this article will be borne by them.

Acknowledgements
We thank the staff of Department of Pharmaceutics and Pharmaceutical Technology, Nnamdi Azikiwe University-Awka, Anambra State, Nigeria, and Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasilia, Brazil, for their material and technical supports to this research. We wish to acknowledge also the INCT, Brazil, that funded the preliminary part of this work.
References

1. Singh S. Confronting the challenges of discovery of novel antibacterial agents. Bioorg Med Chem Lett. 2014; 24:3683-3689.

2. Khan R., Islam B, Akram M, Shakil S, Ahmad A, Ali S.M.et al. Antimicorbiac activity of five herbal extracts against multi drug resistant (MDR) strains of bacteria and fungus of clinical origin. Molecules 2009; 14:586-597.

3. Coutinho HD, CostalGM, Lima EO, Falcão-Silva VS, Siqueira JP. Herbal therapy associated with antibiotic therapy: potentiation of the antibiotic activity against methicillin-resistant S. aureus by Turmera ulmifolia L. BMC Compl Alt Med. 2009; 9:13.

4. Singh R, Shushni MAM, Belkheir A. Antibacterial and antioxidant activities of Mentha piperita L. Arab J Chem 2011; 34:145-192.

5. Samouda R, Kalhari KS, Weerasinghe IS. Insecticidal Activity of Essential Oils of Ceylon Cinnamonum and Cymbopogon species against Musca domestica. J Essent Oil Res. 2006; 18: 352-354.

6. Shah G, Shri R, Panchal V, Sharma N, Singh B, Mann AS. Scientific basis for the therapeutic use of Cymbopogon citratus, (Lemon grass). J. Adv. Pharm. Technol. Res. 2011; 2:3-8.

7. Cermelli C, Fabio A, Fabio G, Quaglio P. Effect of eucalyptus essential oil on respiratory bacteria and viruses. Curr Microbiol. 2006: 58; 89-92.

8. Martins C, Natal-da-Luz T, Sousa JP, Gonçalves MJ, Salgueiro L, Canhoto C. Effects of essential oils from Eucalyptus globulus leaves on soil organisms involved in leaf degradation. PLoS One. 2013; 8:e101233.

9. Nguefack JL, Veth V, Amvam Zollo PH, Mathe SB. Evaluation of five essential oils from aromatic plants of Cameroon for controlling food spoilage and mycotoxin producing fungi. Int. J Food Microbiol. 2004; 94(3):329-334.

10. Schnitzler P, Schön K, Reichling J. Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture. Pharmazie 2001; 56:343-347.

11. Soliman FM, Fathy MM, Salama MM, Saber FR. Chemical composition and bioactivity of the volatile oil from leaves and stems of Eucalyptus cinerea. Pharm Biol. 2014; 15:1–6.

12. Ahmed SM, Ahmad F, Osman SM. Preparation and characterization of derivatives of isoriciolinoic acid and their antimicrobial activity. J Am Oil Chem Soc. 1985; 62:1578–1580.

13. Chen Y, Zeng H, Tian J, Ban X, Ma B, Wang Y. Dill (Anethum graveolens L.) seed essential oil induces Candida albicans apoptosis in a metacaspase-dependent manner. Fungal Biol. 2014; 118:394-401.

14. Singh G, Kapoor IPS, Pandey SK, Singh UK, Singh RK. Studies on essential oils: part 10; Antibacterial activity of volatile oils of some spices. Phytother Res. 2002; 16:680–682.

15. Tian J, Ban X, Zeng H, He J, Chen Y, Wang Y. The mechanism of antifungal action of essential oil from dill (Anethum graveolens L.) on Aspergillus flavus. PLoS One. 2012; 7:e30147.

16. Ledezma E, Apitz-Castro R, Ajoene the main active compound of garlic (Allium sativum): a new antifungal agent. Rev. Iberoam. Micol. 2006; 23:75-80.

17. Booyens J, Thantasra MS. Fourier transform infra-red spectroscopy and flow cytometric assessment of the antibacterial mechanism of action of aqueous extract of garlic (Allium sativum L.) extracts in various localities of Pakistan. Afr J Plant Sci. 2014; 8(6):298-306.

18. Akoachere JFTK, Ndip RN, Chenwi EB, Ndip LM, Njock TE, Anong DN. Antimicrobial effect of Zingiber officinale and Garcinia kola on respiratory tract pathogens. East Afr Med J. 2002; 79:588-592.

19. Gull I, Saeed M, Shaukat H, Aslam SM, Samra ZQ, Athar AM. Inhibitory effect of Allium sativum and Zingiber officinale extracts on clinically important drug resistant pathogenic bacteria. Ann Clin Microbiol Antimicrob. 2012; 11:8.

20. Ficker C, Smith ML, Akpagana K, Gbeassor M, Zhang J, Durst T, Assahghhi R. Bioassay-guided isolation and identification of antifungal compounds from ginger. Phytother Res. 2003; 17:897-902.

21. Picman AK, Schneider EF, Gershenson. J. Antifungal activities of sunflower terpenoids. Biochem Sys Ecol. 1990; 18:325-328.

22. Aboki MA, Mohammed MSH, Musa S H, Zuru B S, Aliyu H M, Gero M, Alibe IM, Inuwa B. Physicochemical and Antimicrobial Properties of Sunflower (Helianthus annuus L.) Seed Oil. Int J Sci Technol. 2012; 2:151-154.

23. Omar HS. Oleuropein in olive and its pharmacochemical effects. Sci Pharm. 2010; 78(2):133-154.

24. Medina E, De Castro A, Romero C, Bremes C. Comparison of the concentrations of phenolic compounds in olive oils and other plant oils; correlation with antimicrobial activity. J Agric Food Chem. 2006; 54; 4954-4961.

25. Lorke D. A new approach to practical acute toxicity testing. Arch Toxicol. 1983; 54:275-287.

26. Norbert WT. Textbook of Clinical Chemistry. Philadelphia, WB. Saunders Company.1986. pp. 1373-1430.28. Dacie JV, Lewis SM. Practical Haematology, Churchill Livingstone, London, 9th ed. 2001; 19-46 p.

27. Reisman, S. and Frankel, S. A Colorimetric Method for Determination of Serum Glutamic Oxalacetic and Glutamic Pyruvic Transaminase. Am J Clin Pathol. 1957; 28:56-63.

28. Bancroft JD and Stevens A. Theory and practice of histological techniques. Longman Inc., New York, 1977; 240 p.

29. Banooee M, Seif S, Nazari ZE, Jafari-Fesharaki P, Shahverdi HR, Moballegh A, Moghaddam KM, Shahverdi AR. ZnO nanoparticles enhanced antibacterial activity of ciprofloxacin against S. aureus and E. coli. J Biomed Mat Res Part B Appl Biomat. 2010; 93:557-561.

30. Chen C, Xing G, Wang J, Zhao Y, Li B, Tang J et al. Multihydroylated [Gd@C82(OH)2]n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano Lett. 2005; 5: 2050-2057.

31. Kaur IP, Bhandari R, Bhandari, S. Potential of solid lipid nanoparticles in brain targeting. J Cont Rel. 2008; 55: 312-333.

32. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Antitumour active parts of the extracts of a medicinal herb (Atractylodes rhizoma). Phytother Res. 1993; 7:228-232.

33. Kaur IP, Bhandari R, Bhandari, S. Potential of solid lipid nanoparticles in brain targeting. J Cont Rel. 2008; 55: 312-333.

34. Kavabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Antitumour active parts of the extracts of a medicinal herb (Atractylodes rhizoma). Phytother Res. 1993; 7:228-232.